Chiesi Farmaceutici has presented data from the long-term TRILOGY and TRINITY studies at the Congress of the European Respiratory Society (ERS) in London.
The TRILOGY study, which shows one-year data on the superior efficacy of the first extrafine formulation fixed ICS/LABA/LAMA triple combination for COPD treatment compared with standard dual therapy, provides support for the triple combination inhaler for the effective long-term treatment of chronic obstructive pulmonary disease (COPD). The inhaler has been specifically formulated to deliver extrafine particles to the lung.
The results of a second pivotal trial, the TRINITY study, were also presented during the Congress, providing evidence of the superiority of ICS/LABA/LAMA also against LAMA alone. The study has proven the superiority of an extrafine formulation of a fixed ICS/LABA/LAMA combination compared to the LAMA alone, another standard therapy for COPD.
COPD affects the respiratory system and particularly the small airways (bronchioles). It presents two different characteristics: an obstructive component that limits airflow especially during expiration, and an inflammatory component, both at the proximal airways and deep lung level. The extrafine formulation of a fixed triple combination tested in the TRILOGY and TRINITY studies is the first containing three different active ingredients that improve airflow and fight inflammation.
Patients with COPD have unmet therapeutic needs, such as reducing the risk of exacerbations that impair the quality of life, lead to hospitalisation and that may even be life-threatening. The possibility of taking all drugs needed by using only one inhaler considerably simplifies the treatment of these patients.